BSE Live
Apr 17, 16:01Prev. Close
1230.75
Open Price
1230.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:59Prev. Close
1230.50
Open Price
1230.50
Bid Price (Qty.)
1240.80 (731)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Cipla (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 27,145.40 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 27,145.40 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | |
| Total Operating Revenues | 27,547.62 | 25,774.09 | 22,753.12 | 21,763.34 | 19,159.59 | |
| Other Income | 861.87 | 746.57 | 475.45 | 280.91 | 265.99 | |
| Total Revenue | 28,409.49 | 26,520.66 | 23,228.57 | 22,044.25 | 19,425.58 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 5,409.60 | 5,220.51 | 5,519.62 | 5,533.13 | 4,886.43 | |
| Purchase Of Stock-In Trade | 3,851.49 | 3,536.03 | 2,828.66 | 3,687.16 | 2,658.17 | |
| Operating And Direct Expenses | 667.72 | 640.62 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -332.10 | 63.03 | -96.00 | -724.69 | -192.71 | |
| Employee Benefit Expenses | 4,832.83 | 4,310.04 | 3,830.08 | 3,529.91 | 3,251.83 | |
| Finance Costs | 62.01 | 89.88 | 109.54 | 106.35 | 160.70 | |
| Depreciation And Amortisation Expenses | 1,106.95 | 1,051.02 | 1,172.11 | 1,051.95 | 1,067.66 | |
| Other Expenses | 5,990.18 | 5,712.81 | 5,643.79 | 5,185.05 | 4,303.44 | |
| Total Expenses | 21,588.68 | 20,623.94 | 19,007.80 | 18,368.86 | 16,135.52 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 6,820.81 | 5,896.72 | 4,220.77 | 3,675.39 | 3,290.06 | |
| Exceptional Items | 0.00 | -194.82 | -182.42 | -182.12 | 0.00 | |
| Profit/Loss Before Tax | 6,820.81 | 5,701.90 | 4,038.35 | 3,493.27 | 3,290.06 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 1,708.35 | 1,696.84 | 1,264.77 | 1,136.90 | 1,052.72 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -178.59 | -150.25 | -61.91 | -203.10 | -163.96 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 1,529.76 | 1,546.59 | 1,202.86 | 933.80 | 888.76 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 5,291.05 | 4,155.31 | 2,835.49 | 2,559.47 | 2,401.30 | |
| Profit/Loss From Continuing Operations | 5,291.05 | 4,155.31 | 2,835.49 | 2,559.47 | 2,401.30 | |
| Profit/Loss For The Period | 5,291.05 | 4,155.31 | 2,835.49 | 2,559.47 | 2,401.30 | |
| Minority Interest | 3.32 | -32.17 | -30.98 | -29.90 | 16.36 | |
| Consolidated Profit/Loss After MI And Associates | 5,272.52 | 4,121.55 | 2,801.91 | 2,516.75 | 2,404.87 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 65.00 | 51.00 | 35.00 | 31.00 | 30.00 | |
| Diluted EPS (Rs.) | 65.00 | 51.00 | 35.00 | 31.00 | 30.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 1,049.83 | 686.17 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
01.04.2026
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth